Physician profile
Nadia Sadik
NPI 1295791861
$3,555.21
in general payments reported to CMS, 2019-2025
30 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $153 · 2021: $295 · 2022: $344 · 2023: $860 · 2024: $681 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,357.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $435.50 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.82 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $236.29 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $185.89 | 2019-2022 | |
| Genzyme Corporation | $138.96 | 2019-2025 | |
| Philips North America LLC | $126.45 | 2019-2025 | Vest Therapy Und |
| Harmony Biosciences LLC | $98.29 | 2021-2023 | Wakix |
| Genentech USA, INC. | $75.25 | 2019-2025 | Xolair |
| United Therapeutics Corporation | $74.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $70.65 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $69.82 | 2019-2024 | |
| Inspire Medical Systems, INC. | $50.80 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $46.63 | 2019-2025 | Dupixent |
| Advanced Respiratory, INC | $43.95 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.30 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $28.88 | 2019-2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2021 | |
| Merck Sharp & Dohme LLC | $25.69 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.62 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.93 | 2025 | Purified Cortrophin Gel |
| Resmed Corp | $18.79 | 2024 | |
| Insmed, INC. | $18.71 | 2025 | Arikayce |
| Avadel Cns Pharmaceuticals, LLC | $18.40 | 2024 | Lumryz |
| Mallinckrodt Enterprises LLC | $13.60 | 2019 | |
| Covidien LP | $13.02 | 2019 | |
| Gilead Sciences, INC. | $12.76 | 2019 | |
| Shire North American Group INC | $12.51 | 2019 | |
| Electromed, INC. | $11.97 | 2022 | |
| Portola Pharmaceuticals, LLC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Sadik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.